Aplicación de la ingeniería tisular en la Enfermedad de Crohn perianal

  1. Saioa Ercoreca Tejada
  2. Miguel Ángel Martín Piedra
  3. Inmaculada Segura Reyes
  4. Raquel Conde Muíño
  5. Tomás Torres Alcalá
  6. Jesús María Villar del Moral
Journal:
Actualidad médica

ISSN: 0365-7965

Year of publication: 2019

Tome: 104

Issue: 807

Pages: 112-117

Type: Article

DOI: 10.15568/AM.2019.807.RE01 DIALNET GOOGLE SCHOLAR lock_openDIGIBUG editor

More publications in: Actualidad médica

Abstract

In this work we have reviewed the most relevant articles that have been published in scientific journals of great impact for the last years in order to know the new therapeutic options in the treatment of the fistulous complications in Crohn's Disease, which widely affect to the quality of life in those patients who suffer from it. Advanced Therapies in this field focus on stem cells as a new approach in the treatment of perianal fistulas of Crohn's patients. Within Tissue Engineering, the method used is the transfer of cells that can come from different sources (mesenchymal or hematopoietic) and with different ways of application (local or systemic) as well as from different origin (allogeneic or autologous). Stem cells can be obtained from adipose tissue, bone marrow or hematopoietic origin. The most frequent form used is from allogenic adipose tissue, administering them locally in the path of the fistula since, this way, there are fewer adverse effects and its obtaining has lower morbidity and mortality compared to the rest of the methods. Cells of hematopoietic origin, up to now, have a relatively high number of adverse effects that do not make them an acceptable option in the treatment of these complications. Currently, despite being an apparently effective and safe treatment, it is completely necessary to have more patients with more homogeneous samples and a longer follow-up over time.

Bibliographic References

  • Panes J, Reinisch W, Rupniewska E, et al. Burden and outcomes for complex perianal fistulas in Crohn's disease: Systematic review. World J Gastroenterol. 2018;24(42):4821–4834.
  • Lightner AL, Faubion WA. Mesenchymal stem cell injections for the treatment of perianal Crohn's disease:what we have accomplished and what we still need to do. J Crohns Colitis. 2017;11:1267–1276.
  • Hernanz N, Sierra M, Volpato N et al. Autologous haematopoietic stem cell transplantation in refractory Crohn's disease: Experience in our centre. Gastroenterol Hepatol. 2019;42(1):16-22.
  • Langer R, Vacanti JP. Tissue engineering. Science. 1993;260:920–6.
  • Mishra PJ, Banerjee D. Activation and Differentiation of Mesenchymal Stem Cells. Methods Mol Biol. 2017. 1554:201-209.
  • Guadix JA, Zugaza JL, Galvez-Martin P. Characteristics, applications and prospects of mesenchymal stem cells in cell therapy. Med Clin. 2017; 148:408–14.
  • Zhang X.M, Zhang Y.J, Wang W, Wei Y.Q, Deng H.X. Mesenchymal Stem Cells to Treat Crohn’s Disease with Fistula. Hum. Gene Ther. 2017;28:534–540.
  • Ciccocioppo R, Bernardo M. E, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011;60(6):788–798.
  • Naderi N, Combellack E. J, Griffin M, et al. The regenerative role of adipose-derived stem cells (ADSC) in plastic and reconstructive surgery. Int Wound J. 2017;14(1):112–124.
  • Martin-Piedra MA, Alfonso-Rodriguez CA, Zapater A et al. Effective use of mesenchymal stem cells in human skin substitutes generated by tissue engineering. Eur Cell Mater. 2019;29;37:233-249.
  • De la Portilla F, Alba F, Garcia-Olmo D, Herrerias J.M, Gonzalez F.X, Galindo A. Expanded allogeneic adiposederived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: Results from a multicenter phase I/IIa clinical trial. Int. J. Colorectal. Dis. 2013;28:313–323.
  • Panés J, García-Olmo D, Van Assche G et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281–1290.
  • Panés J, García-Olmo D, Van Assche G et al. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease. Gastroenterology. 2018;154:1334–1342.
  • Garcia-Arranz M, et al. Treatment of Crohn’s-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I-IIa Clinical Trial. Stem Cells Transl Med. 2016;5:1441–1446.
  • García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rect. (2005) 48:1416–23.
  • Garcia-Olmo D, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18:451–454.
  • Lightner AL, Wang Z, Zubair AC, Dozois EJ. A Systematic Review and Meta-analysis of Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn’s Disease: Progress Made and Future Directions. Dis Colon Rectum. 2018;61:629–640.
  • Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther. 2008;8:1417–23.
  • Tozer PJ, Burling D, Gupta A. et al. Review article: medical, surgical and radiological management of perianal Crohn’s fistulas. Aliment Pharmacol Ther 2011;33:5–22.
  • Kagami H, Agata H, Tojo A. Bone marrow stromal cells (bone marrow-derived multipotent mesenchymal stromal cells) for bone tissue engineering: basic science to clinical translation. Int J Biochem Cell Biol. 2011;43:286–9.
  • Bianco P., Robey P. G., Simmons P. J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2(4):313–319.
  • Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G. et al. Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2015;149:918– 27.
  • Ciccocioppo R, Gallia A, Sgarella A, Kruzliak P, Gobbi PG, Corazza GR. Long-term follow-up of Crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells. Mayo Clin Proc. 2015;90(6):747–755.
  • Turse EP, Dailey FE, Naseer M, Partyka EK, Bragg JD, Tahan V. Stem cells for luminal, fistulizing, and perianal inflammatory bowel disease: a comprehensive updated review of the literature. Stem Cells Cloning. 2018;11:95-113.
  • Hawkey CJ, Allez M, Clark MM et al. Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. JAMA. 2015;314(23):2524-34.
  • López-García A, Rovira M, Jauregui-Amezaga A, et al. Autologous haematopoietic stem cell transplantation for refractory Crohn’s disease: efficacy in a single-centre cohort. J Crohns Colitis. 2017;11(10):1161–1168.
  • Brierley CK. Castilla-Llorente C. Labopin M, et al. A retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation. J Crohns Colitis. 2018;12(9): 1097–1103.
  • Snowden JA, Panés J, Alexander T, et al. Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn’s disease: a review on behalf of ECCO and EBMT. J Crohns Colitis. 2018;12(4):476–488.
  • Lindsay JO, Allez M, Clark M, et al. Autologous stem-cell transplantation in treatment-refractory Crohn’s disease: an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol Hepatol. 2017;2(6):399–406.
Data source: Dialnet